The only cancer vaccine that has been approved thus far— sipuleucel-T for prostate cancer—relies on the fusion of a prostate cancer antigen to GM-CSF, which is then loaded into autologous peripheral blood monocytes thought to be predominantly dendritic cells. Here, CSF2 is linked to prostate carcinoma.